Tag Archives: Food and Drug Administration
-
In October, 2010, the U.S. Food and Drug Administration (FDA) approved the drug dabigatran to reduce the risk of blood clots and stroke in patients with atrial fibrillation. Marketed as the twice-daily miracle drug Pradaxa, dabigatran is now suspected in more than 540 patient deaths and thousands of drug injuries. Side effects of Pradaxa are… Read More »
